Currently, new therapeutic drugs for ankylosing spondylitis mainly include biological agents such as adalimumab, infliximab and etanercept.
Ankylosing spondylitis is mainly treated with medication, and surgery can be used if necessary. Commonly used medications include non-steroidal anti-inflammatory drugs (NSAIDs) such as Loxoprofen Sodium, Etoricoxib and immunosuppressant drugs such as Leflunomide and Methotrexate, whereas biologics such as Adalimumab, Infliximab, and Etanercept belong to the newer types of therapeutic drugs.
Biologics such as adalimumab, infliximab and etanercept are tumor necrosis factor-alpha inhibitors, which are indicated for ankylosing spondylitis and can improve the patient’s condition. The above drugs can cause adverse reactions such as serious infections and malignant tumors. They are contraindicated in people who are allergic to the product or other ingredients in the preparation; active tuberculosis or other serious infectious diseases.
Precautions: Before, during and after the use of the above drugs, patients must be closely monitored for infections, including tuberculosis.
The above drugs should be used under the guidance of a professional physician, and it is recommended that patients with ankylosing spondylitis go to the rheumatology and immunology department of a regular hospital for consultation and standardized diagnosis and treatment according to the doctor’s instructions.